Skip to content
Biodatica
Start free

Guangzhou Lupeng Pharmaceutical Company LTD.

Guangzhou, Guangdong

OncologyCAR-TPhase II
Compare Sign in to watch

What changed

Phase II trial registered: Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma

6w agoTrial registeredJun 3, 2026Source filing (opens the source filing in a new tab)

Momentum

87no change

Momentum 87 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

681 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Sep 1, 2026

    Follicular Lymphoma (FL) · NOT_YET_RECRUITING · sponsor: Sun Yat-sen University · Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma

    ClinicalTrials.gov · NCT07550855 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Jun 1, 2026

    Relapsed or Refractory B-cell Lymphoma · NOT_YET_RECRUITING · sponsor: Sun Yat-sen University · Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma

    ClinicalTrials.gov · NCT07622784 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Sep 15, 2025

    Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL) · RECRUITING · sponsor: Sun Yat-sen University · Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

    ClinicalTrials.gov · NCT07077512 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Apr 10, 2024

    B-cell Non-Hodgkin Lymphoma · RECRUITING · sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. · Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

    ClinicalTrials.gov · NCT06251180 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Jul 15, 2022

    Resolved Hepatitis B, CD20 Positive B-cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Sun Yat-sen University · Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)

    ClinicalTrials.gov · NCT05453435 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources